Valley Fever in Dogs: Coccidioidomycosis in Endemic Areas

Valley Fever is the common name for coccidioidomycosis, a fungal infection caused by Coccidioides immitis and Coccidioides posadasii — soil-dwelling fungi endemic to the arid and semi-arid regions of the southwestern United States, Mexico, and parts of Central and South America. The disease gets its colloquial name from the San Joaquin Valley in California where it was first identified, but today Arizona is the epicentre, with the Phoenix and Tucson metropolitan areas reporting the highest infection rates in both humans and dogs.

"Valley Fever is the single most common serious infectious disease I diagnose in dogs living in the desert Southwest. In endemic areas like Arizona, I tell every new dog owner to learn the symptoms — early detection makes the difference between a straightforward treatment course and a potentially life-threatening disseminated infection." — Dr. Sarah Chen, DVM

The Coccidioides fungus lives in the top few inches of desert soil in a filamentous (mould) form. When soil is disturbed — by construction, digging, dust storms, agricultural activity, or even a dog's enthusiastic nose rooting through the ground — the fungal filaments break into tiny spores called arthroconidia. These microscopic spores become airborne and are inhaled into the lungs, where they transform into a completely different form: large, round structures called spherules that are filled with hundreds of smaller endospores. When the spherule ruptures, it releases endospores that each develop into new spherules, perpetuating the infection cycle within the body.

Dogs are significantly more susceptible to Valley Fever than humans, cats, or most other domestic animals. Their natural behaviours — sniffing the ground, digging in soil, running through dusty terrain — maximise their exposure to airborne spores. Studies suggest that in highly endemic areas, the majority of outdoor dogs will test positive for Coccidioides exposure at some point, though only a fraction develop clinical disease. The immune system of most healthy dogs can contain the initial lung infection without treatment, but a significant percentage go on to develop symptomatic disease requiring medical intervention.

The sole route of Valley Fever infection is inhalation of Coccidioides arthroconidia (spores) from contaminated soil. The fungus cannot be transmitted from dog to dog, dog to human, or from any animal to another through direct contact, bodily fluids, or shared items. Every case of Valley Fever represents an individual encounter between the dog's respiratory tract and fungal spores in the environment.

Several environmental scenarios dramatically increase the risk of exposure. Construction sites and land development are major risk factors — earth-moving activities release massive quantities of spores from previously undisturbed soil. Dogs living near active construction zones in endemic areas face substantially higher infection rates. Dust storms (haboobs), which are common in Arizona during monsoon season, can carry Coccidioides spores for miles, exposing dogs and people far from the original soil source. Even routine activities like gardening, desert hiking, or simply letting a dog dig in the yard can result in spore inhalation.

Certain risk factors make some dogs more likely to develop clinical disease after exposure. Young dogs (under four years of age) are overrepresented in clinical cases, likely because they lack prior immunological exposure. Large breeds, particularly Boxers, Pointers, Beagles, Scottish Terriers, and Doberman Pinschers, appear to be at higher risk of disseminated disease, though any breed can be affected. Immunosuppressed dogs — those on corticosteroids, chemotherapy, or with concurrent immune-mediated diseases — face a significantly elevated risk of both primary infection and dissemination.

Seasonality also plays a role. Infection rates tend to peak in late summer and autumn, corresponding to the dry, dusty period following the monsoon rains. The rain stimulates fungal growth in the soil, and the subsequent dry conditions promote spore dispersal. However, Valley Fever can be contracted at any time of year, and dogs new to endemic areas are particularly vulnerable regardless of season because they lack any prior immune priming against the organism.

Valley Fever in dogs manifests in two broad clinical forms: primary respiratory disease and disseminated disease. The initial infection is always respiratory (since spores enter through the lungs), but in a significant percentage of dogs, the fungus escapes the lungs and spreads to other body systems — a development that substantially complicates treatment and worsens the prognosis.

Primary respiratory Valley Fever typically develops two to four weeks after spore inhalation and presents with symptoms that can easily be mistaken for other common respiratory conditions. The most frequent signs include a persistent dry cough that does not respond to antibiotics, fever (often low-grade and intermittent), lethargy and reduced energy, decreased appetite, and weight loss. Some dogs develop mild to moderate difficulty breathing. In many cases, the symptoms are subtle enough that owners attribute them to a minor illness or seasonal allergies, particularly in the early stages. If you notice your dog is showing signs of discomfort or pain alongside a persistent cough, Valley Fever should be considered if you live in or have recently visited an endemic area.

Disseminated Valley Fever occurs when the fungus spreads beyond the lungs via the bloodstream. The most common site of dissemination is the bones and joints, causing lameness that may shift between legs, joint swelling, and visible bone enlargement — often affecting the long bones of the legs. Dogs with bone involvement are typically very painful and reluctant to exercise. The skin is another frequent target, with nodules, draining tracts, and non-healing ulcers appearing anywhere on the body. Eye involvement can cause redness, cloudiness, discharge, and if untreated, permanent vision loss.

The most serious form of disseminated Valley Fever involves the central nervous system (brain and spinal cord). Dogs with CNS involvement may develop seizures, head tilt, circling, incoordination, or dramatic behavioural changes. CNS Valley Fever carries the most guarded prognosis and typically requires lifelong antifungal therapy. Any dog in an endemic area that develops seizures of unknown origin should be tested for Valley Fever as part of the diagnostic workup.

The cornerstone of Valley Fever diagnosis in dogs is the Valley Fever titer (antibody test), which measures the level of antibodies the dog's immune system has produced against Coccidioides. The test is performed on a simple blood sample and is widely available through veterinary reference laboratories, particularly in endemic areas. The result is expressed as a titer ratio (e.g., 1:4, 1:16, 1:256), with higher titers generally indicating more active or extensive disease.

Interpreting Valley Fever titers requires clinical context. A low positive titer (1:2 to 1:4) in a dog with compatible symptoms suggests early or mild infection. A moderate titer (1:8 to 1:16) in a symptomatic dog is considered diagnostic. High titers (1:32 and above) often indicate disseminated disease or a heavy fungal burden. However, titers can be negative in the first two to four weeks of infection (before the immune system mounts a detectable antibody response), so a negative titer does not rule out Valley Fever if the dog has been symptomatic for less than a month. Retesting in three to four weeks is recommended in suspicious cases with initially negative results.

Chest X-rays (thoracic radiographs) are an important complement to serology. Lung lesions in Valley Fever can range from diffuse interstitial patterns (a hazy appearance throughout the lungs) to discrete nodular lesions or hilar lymph node enlargement. Some dogs develop large granulomas visible as distinct round masses. X-rays of the limbs are used when bone involvement is suspected, revealing characteristic lytic (destructive) bone lesions with surrounding periosteal reaction. Advanced imaging (CT or MRI) may be needed for spinal or CNS disease evaluation.

Cytology — microscopic examination of samples from draining wounds, lymph node aspirates, or joint fluid — can sometimes reveal the characteristic Coccidioides spherules directly. When present, spherules are highly distinctive: large, round, thick-walled structures filled with small endospores, unlike anything else seen on cytology. However, finding spherules in cytological samples is the exception rather than the rule, and a negative cytology does not exclude the diagnosis. The combination of compatible clinical signs, a positive titer, and supportive imaging findings is sufficient for confident diagnosis in the vast majority of cases. Regular veterinary visits on the recommended schedule are especially important for dogs in endemic regions.

The treatment of Valley Fever in dogs centres on oral antifungal medications, with the specific drug, dose, and duration determined by the severity and extent of disease. Unlike bacterial infections that can often be cured with a short course of antibiotics, fungal infections require prolonged therapy measured in months to years — a reality that owners in endemic areas must be prepared for both financially and logistically.

Fluconazole is the first-line antifungal for most Valley Fever cases in dogs. It is effective, generally well-tolerated, and relatively affordable compared to other antifungal agents. The standard dose ranges from 5-10 mg/kg given once or twice daily, and treatment duration is a minimum of six to twelve months for uncomplicated respiratory disease. Fluconazole is particularly effective for lung, skin, and soft tissue involvement. It also penetrates the blood-brain barrier well, making it the preferred agent for CNS disease — though CNS cases typically require lifelong therapy because relapse rates are high when treatment is discontinued.

Itraconazole is the preferred alternative for cases involving bone and joint disease, where it appears to achieve better tissue concentrations than fluconazole. The dose is typically 5 mg/kg twice daily. Itraconazole can cause liver toxicity in some dogs, so periodic liver enzyme monitoring is recommended during treatment. Ketoconazole, an older antifungal, is less commonly used today due to higher rates of side effects including appetite loss, liver toxicity, and hormonal disruption, but it remains an option when cost is a primary constraint.

Treatment response is monitored through a combination of clinical improvement and serial Valley Fever titer testing, typically performed every three to four months. A declining titer indicates the infection is responding to treatment. The general guideline is to continue antifungal therapy for at least twelve months after clinical signs resolve AND the titer has dropped to negative or a very low level (1:2 or less). Stopping treatment too early is the most common cause of relapse. Some dogs with disseminated disease require years of continuous therapy, and a subset — particularly those with bone or CNS involvement — may need lifelong medication. Given the extended treatment duration, having pet insurance in place before your dog is diagnosed can significantly reduce the financial burden.

If you live in or are moving to a Valley Fever endemic area — particularly Arizona, the Central Valley of California, southern Nevada, southern New Mexico, or west Texas — there are practical steps you can take to reduce your dog's risk of exposure, even though complete prevention is not possible while allowing dogs any outdoor activity.

Limit digging behaviour. Dogs that actively dig in desert soil have significantly higher rates of Valley Fever infection. Discourage digging through training, provide alternative enrichment activities, and consider yard modifications that reduce access to bare desert soil. Gravel, artificial turf, or desert-adapted landscaping with ground cover can reduce the amount of exposed soil in your immediate environment.

Avoid dust storms and high-wind conditions. During haboob warnings or high-wind advisories in endemic areas, keep your dog indoors with windows closed. If you must take your dog outside, keep outings brief and stick to paved surfaces. The period immediately after a dust storm, when settled dust can still be disturbed, also carries elevated risk.

Yard maintenance matters. Regularly water or irrigate your yard to keep soil moist and reduce dust. Avoid activities that disturb large amounts of soil — if you are landscaping or doing construction, keep your dog away from the work area. If possible, replace bare desert soil with rock, gravel, or artificial surfaces in the areas your dog uses most frequently.

There is no reliable vaccine yet, though research into a Valley Fever vaccine for dogs has been ongoing for years, with several promising candidates in development. Until a vaccine becomes available, environmental management and early detection remain the cornerstones of prevention. Know the symptoms — particularly persistent cough, unexplained lameness, and fever — and request a Valley Fever titer if your dog develops any concerning signs. Early diagnosis and treatment dramatically improve outcomes compared to advanced or disseminated disease discovered later.

Finally, be aware that dogs new to endemic areas are at particular risk during their first one to two years of residence, before their immune system has any prior exposure to Coccidioides. If you are relocating to Arizona or another endemic region with your dog, discuss Valley Fever awareness with a local veterinarian upon arrival and establish a baseline titer so future results can be compared.